Fig. 7: Targeting CREB3L2 reverses lenvatinib resistance in HCC. | Cell Death & Disease

Fig. 7: Targeting CREB3L2 reverses lenvatinib resistance in HCC.

From: Targeting CREB3L2-mediated lipid metabolism overcomes lenvatinib resistance and attenuates the progression of hepatocellular carcinoma

Fig. 7

A, B Silencing CREB3L2 in 97H cells significantly increases sensitivity to lenvatinib. C Determination of cell viability in 97H cells treated with lenvatinib using the CCK-8 assay. D Suppression of CREB3L2 expression markedly enhances lenvatinib-mediated inhibition of tumor cell malignant phenotypes. E Knockdown of CREB3L2 enhances the inhibitory effect of lenvatinib on SREBP1 expression. F, G Xenograft tumor growth of 97H cells with CREB3L2 knockdown treated with lenvatinib. H Representative lung metastasis sections from different treatment groups of nude mice. I A simple mechanistic diagram for the entire text. *P < 0.05; **P < 0.01; ***P < 0.001.

Back to article page